Literature DB >> 29202377

Quantifying the prognostic significance in glioblastoma of seizure history at initial presentation: A systematic review and meta-analysis.

Victor M Lu1, Toni R Jue2, Kevin Phan3, Kerrie L McDonald2.   

Abstract

The role of prognostic factors in the management of glioblastoma (GBM) is very important given the stasis in improving its clinical outcomes. Patients who initially present with a positive seizure history at diagnosis have anecdotally experienced superior survival outcomes. The aim of this review was to perform a systematic review and meta-analysis to quantify the potential prognostic significance of positive seizure history in GBM patients. A search strategy was performed using the PRISMA guidelines for article identification, screening, eligibility and inclusion. Relevant articles were identified from six electronic databases from their inception to August 2017. These articles were screened against established criteria for inclusion into this study. Meta-analysis was conducted by pooling results with multivariate-adjusted hazard ratios (HRs). After screening, 6 relevant studies were included for analysis. There was a total cohort of 1836 GBM patients, of which 488 (27%) had a positive seizure history at initial presentation. There was a significant association found between positive seizure history in GBM patients and less mortality events, with an overall HR of 0.71 (95%CI=0.63-0.81, p<0.00001, I2=4%). Positive seizure history at initial presentation of GBM can be associated with improved prognosis. However, there are a number of variables that need to be considered further, including genetic profiling, lead time bias, and anti-epileptic drug (AED) therapy. This review represents the highest level of evidence to date, and its result will be validated by future, prospective study of larger cohorts.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epilepsy; Glioblastoma; Meta-analysis; Seizure; Survival

Mesh:

Year:  2017        PMID: 29202377     DOI: 10.1016/j.clineuro.2017.11.015

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  3 in total

1.  Preoperative and early postoperative seizures in patients with glioblastoma-two sides of the same coin?

Authors:  Yahya Ahmadipour; Laurèl Rauschenbach; Alejandro Santos; Marvin Darkwah Oppong; Lazaros Lazaridis; Carlos M Quesada; Andreas Junker; Daniela Pierscianek; Philipp Dammann; Karsten H Wrede; Björn Scheffler; Martin Glas; Martin Stuschke; Ulrich Sure; Ramazan Jabbarli
Journal:  Neurooncol Adv       Date:  2020-11-18

2.  Non-invasively measured brain activity and radiological progression in diffuse glioma.

Authors:  T Numan; S D Kulik; B Moraal; J C Reijneveld; C J Stam; P C de Witt Hamer; J Derks; A M E Bruynzeel; M E van Linde; P Wesseling; M C M Kouwenhoven; M Klein; T Würdinger; F Barkhof; J J G Geurts; A Hillebrand; L Douw
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

3.  The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial.

Authors:  Maoyuan Sun; Ning Huang; Yihao Tao; Rong Wen; Guanjian Zhao; Xiang Zhang; Zongyi Xie; Yuan Cheng; Jinning Mao; Guodong Liu
Journal:  Trials       Date:  2022-03-28       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.